Literature DB >> 15141379

CK20 expression, CDX2 expression, K-ras mutation, and goblet cell morphology in a subset of lung adenocarcinomas.

Yasushi Yatabe1, Takaomi Koga, Tetsuya Mitsudomi, Takashi Takahashi.   

Abstract

There are data in the literature that suggest a close relationship between the expression of CK20 and CDX2, K-ras mutations, and goblet cell morphology. The present study has examined these factors in a cohort of 264 non-small cell lung cancers. Thirteen of 212 adenocarcinomas expressed CK20; 29 expressed CDX2; K-ras mutation was identified in 28; and goblet cell features were present in 19. These four factors correlated with each other in a complex way and therefore a logistic regression model was constructed. Significant correlations were found between CK20 and CDX2 expression, and between K-ras mutation and goblet cell morphology, and there was a marginal correlation between CDX2 immunoreactivity and goblet cell morphology. These four features have also been commonly detected in colorectal, pancreato-biliary, and ovarian mucinous carcinomas, suggesting that these adenocarcinomas may be prototypical, independent of the organ of origin. Furthermore, as high and uniform expression of CDX2 was characteristic of metastatic colorectal cancer, weak and/or focal CDX2 expression should alert surgical pathologists to the possibility of primary lung adenocarcinoma, especially in the presence of goblet cell morphology. However, some lung adenocarcinomas may express CDX2 strongly: in this case, CK20 also tends to be positive. Copyright 2004 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15141379     DOI: 10.1002/path.1566

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  16 in total

1.  Pros: the present classification of mucinous adenocarcinomas of the lung.

Authors:  Sanja Dacic
Journal:  Transl Lung Cancer Res       Date:  2017-04

2.  Prognostic value of K-ras mutation status and subtypes in endoscopic ultrasound-guided fine-needle aspiration specimens from patients with unresectable pancreatic cancer.

Authors:  Takeshi Ogura; Kenji Yamao; Kazuo Hara; Nobumasa Mizuno; Susumu Hijioka; Hiroshi Imaoka; Akira Sawaki; Yasumasa Niwa; Masahiro Tajika; Shinya Kondo; Tsutomu Tanaka; Yasuhiro Shimizu; Vikram Bhatia; Kazuhide Higuchi; Waki Hosoda; Yasushi Yatabe
Journal:  J Gastroenterol       Date:  2012-09-15       Impact factor: 7.527

Review 3.  International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma.

Authors:  William D Travis; Elisabeth Brambilla; Masayuki Noguchi; Andrew G Nicholson; Kim R Geisinger; Yasushi Yatabe; David G Beer; Charles A Powell; Gregory J Riely; Paul E Van Schil; Kavita Garg; John H M Austin; Hisao Asamura; Valerie W Rusch; Fred R Hirsch; Giorgio Scagliotti; Tetsuya Mitsudomi; Rudolf M Huber; Yuichi Ishikawa; James Jett; Montserrat Sanchez-Cespedes; Jean-Paul Sculier; Takashi Takahashi; Masahiro Tsuboi; Johan Vansteenkiste; Ignacio Wistuba; Pan-Chyr Yang; Denise Aberle; Christian Brambilla; Douglas Flieder; Wilbur Franklin; Adi Gazdar; Michael Gould; Philip Hasleton; Douglas Henderson; Bruce Johnson; David Johnson; Keith Kerr; Keiko Kuriyama; Jin Soo Lee; Vincent A Miller; Iver Petersen; Victor Roggli; Rafael Rosell; Nagahiro Saijo; Erik Thunnissen; Ming Tsao; David Yankelewitz
Journal:  J Thorac Oncol       Date:  2011-02       Impact factor: 15.609

4.  Corticosteroids correct aberrant CFTR localization in the duct and regenerate acinar cells in autoimmune pancreatitis.

Authors:  Shigeru B H Ko; Nobumasa Mizuno; Yasushi Yatabe; Toshiyuki Yoshikawa; Hiroshi Ishiguro; Akiko Yamamoto; Sakiko Azuma; Satoru Naruse; Kenji Yamao; Shmuel Muallem; Hidemi Goto
Journal:  Gastroenterology       Date:  2010-01-15       Impact factor: 22.682

5.  Mutations of the EGFR and K-ras genes in resected stage I lung adenocarcinoma and their clinical significance.

Authors:  Taro Ohba; Gouji Toyokawa; Takuro Kometani; Kaname Nosaki; Fumihiko Hirai; Masafumi Yamaguchi; Motoharu Hamatake; Takashi Seto; Yukito Ichinose; Kenji Sugio
Journal:  Surg Today       Date:  2013-04-23       Impact factor: 2.549

6.  Pulmonary mucinous adenocarcinomas: architectural patterns in correlation with genetic changes, prognosis and survival.

Authors:  Abidin Geles; Ulrike Gruber-Moesenbacher; Franz Quehenberger; Claudia Manzl; Mohamed Al Effah; Elisabeth Grygar; Freyja Juettner-Smolle; Helmut H Popper
Journal:  Virchows Arch       Date:  2015-10-08       Impact factor: 4.064

7.  Association between the histological subtype of lung adenocarcinoma, EGFR/KRAS mutation status and the ALK rearrangement according to the novel IASLC/ATS/ERS classification.

Authors:  Yu-Jie Dong; Yi-Ran Cai; Li-Juan Zhou; Dan Su; Jing Mu; Xue-Jing Chen; L I Zhang
Journal:  Oncol Lett       Date:  2016-02-17       Impact factor: 2.967

8.  Impact of K-Ras Over-expression in Laryngeal Squamous Cell Carcinoma.

Authors:  Vasileios Papanikolaou; Aristeidis Chrysovergis; Stylianos Mastronikolis; Evangelos Tsiambas; Vasileios Ragos; Dimitrios Peschos; Despoina Spyropoulou; Pavlos Pantos; Athanasios Niotis; Nicholas Mastronikolis; Efthymios Kyrodimos
Journal:  In Vivo       Date:  2021 May-Jun       Impact factor: 2.155

9.  Foxa2 and Cdx2 cooperate with Nkx2-1 to inhibit lung adenocarcinoma metastasis.

Authors:  Carman Man-Chung Li; Vasilena Gocheva; Madeleine J Oudin; Arjun Bhutkar; Shi Yun Wang; Saya R Date; Sheng Rong Ng; Charles A Whittaker; Roderick T Bronson; Eric L Snyder; Frank B Gertler; Tyler Jacks
Journal:  Genes Dev       Date:  2015-09-01       Impact factor: 11.361

10.  The Role of KRAS Mutational Analysis to Determine the Site of Origin of Metastatic Carcinoma to the Lung: A Case Report.

Authors:  Ahmad Alkhasawneh; Ahmed N Alkhasawneh; Hui-Jia Dong; Chen Liu; Carmen Allegra; Robert W Allan
Journal:  Case Rep Pathol       Date:  2012-10-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.